Your search for psilocybin returned 3 results

The trial will be a Phase 2b dose-ranging study (N=216) with patients from 12-15 research centers across Europe and North America.

Results from a recent study published in The Lancet Psychiatry demonstrates preliminary support for the safety and efficacy of the hallucinogenic compound, psilocybin, for the management of treatment-resistant depression.

According to a study in The American Journal of Drug and Alcohol Abuse, psilocybin showed promise in promoting long-term smoking abstinence in the context of a structured treatment program.